GlassScriptPhysician profile
Thomas Wilkins
NPI 1083061568
$2,843.22
in general payments reported to CMS, 2019-2025
26 companies · $856 in 2025
The $856 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.65 · 2020: $100 · 2021: $207 · 2022: $12.84 · 2023: $590 · 2024: $1,028 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,473.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $389.98 | 2023-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $380.29 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $340.13 | 2023-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $233.02 | 2023-2025 | Rexulti |
| Pfizer INC. | $189.26 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $142.18 | 2023-2025 | Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.29 | 2024-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $119.13 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $114.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Intuitive Surgical, INC. | $112.23 | 2025 | |
| Abbott Laboratories | $101.06 | 2023-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $95.58 | 2023-2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $78.36 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $70.91 | 2023-2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.64 | 2020-2024 | Tradjenta, Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $50.44 | 2021-2022 | |
| Inspire Medical Systems, INC. | $45.95 | 2025 | Inspire |
| Medtronic, INC. | $31.25 | 2023 | Corevalve Evolut R |
| Vanda Pharmaceuticals INC. | $29.83 | 2025 | Fanapt |
| Tactile Systems Technology INC | $28.18 | 2024 | Entre Plus, Flexitouch Plus |
| Lundbeck LLC | $21.62 | 2024 | Rexulti |
| Allergan, INC. | $20.91 | 2019 | |
| Dexcom, INC. | $20.20 | 2025 | Dexcom G6 Transmitter |
| Halozyme INC | $17.32 | 2023 | |
| Janssen Pharmaceuticals, INC | $14.81 | 2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $14.30 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Wilkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.